Cargando…

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer

Patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR benefit from treatment with EGFR small-molecule tyrosine-kinase inhibitors. However, the development of acquired resistance to EGFR inhibitors is universal and limits treatment efficacy. Over half of patients rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Phu N, Klempner, Samuel J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310702/ https://www.ncbi.nlm.nih.gov/pubmed/28210165 http://dx.doi.org/10.2147/LCTT.S94337

Ejemplares similares

New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?
por: Van Der Steen, Nele, et al.
Publicado: (2016)

Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo
por: Zeng, Fanpu, et al.
Publicado: (2020)

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
por: Tran, Phu N., et al.
Publicado: (2016)

LC–MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation
por: Attwa, Mohamed W, et al.
Publicado: (2021)

Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
por: Tran, Phu, et al.
Publicado: (2016)

Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
por: Stasi, Irene, et al.
Publicado: (2014)

The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer: A population-based analysis
por: Tran, Phu N., et al.
Publicado: (2017)

PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence
por: Tran, Phu N, et al.
Publicado: (2017)

Torsades de pointes with pseudo–T wave alternans during rociletinib therapy: A novel manifestation of a rare side effect
por: Teng, Alexandra E., et al.
Publicado: (2018)

Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)
por: Fawwaz, Muammar, et al.
Publicado: (2020)

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
por: Yang, James Chih-Hsin, et al.
Publicado: (2020)

Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
por: Cooper, Maryann R, et al.
Publicado: (2016)

SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer
por: Yang, Libang, et al.
Publicado: (2023)

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
por: Ang, Yvonne LE, et al.
Publicado: (2016)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns, Mark W, et al.
Publicado: (2015)

Molecular profiling of non-small cell lung cancer
por: Forsythe, Marika L., et al.
Publicado: (2020)

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2013)

Serum level of DKK-1 and its prognostic potential in non–small cell lung cancer
por: Dong, Liang-liang, et al.
Publicado: (2014)

MicroRNA-222 Expression and Its Prognostic Potential in Non-Small Cell Lung Cancer
por: Mao, Kai-ping, et al.
Publicado: (2014)

Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer
por: Hijazo-Pechero, Sara, et al.
Publicado: (2021)

Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations
por: Tang, Chunyin, et al.
Publicado: (2022)

Non-thermal plasma treatment altered gene expression profiling in non-small-cell lung cancer A549 cells
por: Hou, Jue, et al.
Publicado: (2015)

Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer
por: Cunningham, Charnay, et al.
Publicado: (2023)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
por: Facchinetti, Francesco, et al.
Publicado: (2018)

Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population
por: Dang, Anh-Thu Huynh, et al.
Publicado: (2020)

The methylation profiles of PRDM promoters in non–small cell lung cancer
por: Tan, Shuang-xiang, et al.
Publicado: (2018)

Molecular profile of non-small cell lung cancer in northeastern Brazil
por: de Oliveira, Ana Claudia da Silva Mendes, et al.
Publicado: (2019)

Roles of Lipid Profiles in Human Non-Small Cell Lung Cancer
por: Jianyong, Zhang, et al.
Publicado: (2021)

Extracellular RNA profiles in non-small cell lung cancer plasma
por: Ni, Yaojun, et al.
Publicado: (2023)

Genomic profiling and sites of metastasis in non-small cell lung cancer
por: Chan, Kok Hoe, et al.
Publicado: (2023)

Targeting regulation of VEGF by BPTF in non-small cell lung cancer and its potential clinical significance
por: Dai, Meng, et al.
Publicado: (2022)

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer
por: Spaans, Johanna N., et al.
Publicado: (2014)

Immunotherapy and the Treatment of Non–Small Cell Lung Cancer
por: Walker, Suzanne
Publicado: (2016)

Individualization of treatment in non-small cell lung cancer
por: van Zandwijk, Nico
Publicado: (2009)

Aptamers in Non-Small Cell Lung Cancer Treatment
por: Wieleba, Irena, et al.
Publicado: (2020)

Sintilimab for the treatment of non-small cell lung cancer
por: Zhang, Lin, et al.
Publicado: (2022)

Current treatments for non-small cell lung cancer
por: Guo, Qianqian, et al.
Publicado: (2022)

Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments
por: Alifrangis, Costi, et al.
Publicado: (2018)

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
por: Botticelli, Andrea, et al.
Publicado: (2020)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sg1oqsfirj0q2bap7v67fdb7qp